STAT+: Pharmalittle: Moderate House Dems’ opposition to drug-pricing reforms shrinks; Glaxo goes on charm offensive
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Category: STAT+
STAT+: In May, 10 moderate Democrats opposed major drug pricing reform. Ahead of a key vote, that list is shrinking
WASHINGTON — Ten House Democrats fired a warning shot in the spring that they could…
STAT+: Epic’s sepsis algorithm is going off the rails in the real world. The use of these variables may explain why
In marketing materials and internal documents, national electronic health record vendor Epic Systems has touted…
STAT+: WHO adds Regeneron drug to recommended Covid-19 treatments, but criticizes its pricing
The World Health Organization added a Regeneron Pharmaceuticals medication to its list of recommended treatments…
STAT+: Pharmalittle: CDC director overrules panel and recommends Pfizer shot for at-risk workers; DOD watchdog faults military over pharma supply chain issues
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Defense Department watchdog criticizes oversight of military’s pharmaceutical supply chain
Amid mounting concerns over the U.S. pharmaceutical supply chain, a Department of Defense watchdog found…
STAT+: Pharmalittle: Pfizer CEO rallies employees to fight drug-price negotiations; Glaxo head pressured by another activist fund
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: ‘It’s never one-size-fits all’: Health tech leaders look to design to make care more equitable
At the opening of each of her clinics, there’s a moment when Carolyn Witte, the…
STAT+: The ‘Great Resignation’ could be health tech’s next big sales pitch
Innovative health companies hoping to boost sales are playing into one of the biggest fears…
.jpg)
STAT+: Federal officials move closer to penalizing drug makers for failing to offer discounts to safety-net hospitals
Following a year of controversy, the Health Resources and Services Administration is taking steps to…
STAT+: Compound pharmacies win court battle over an FDA plan for monitoring shipments
A U.S. federal court judge has ruled that an effort by the Food and Drug…
STAT+: Pharmalittle: Biogen considers layoffs amid poor Alzheimer’s drug sales; House Dems plan showdown on drug-pricing vote
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Biogen’s Aduhelm sales slower than disclosed, forcing company to consider cost-cutting measures
Earlier this month, Biogen executives admitted publicly that the launch of Aduhelm, its treatment for…
STAT+: Pharmalittle: J&J says its Covid-19 shot is more effective in two doses; India plans to resume Covid-19 vaccine exports
Top of the morning to you, and a fine one it is. Sunny skies and…
STAT+: U.S. lawmakers accuse patent office of weakening patent challenges and allowing drug prices to rise
A bipartisan group of lawmakers has accused the U.S. Patent & Trademark Office of “weakening”…
STAT+: Citing competitive concerns, European Commission seeks to intervene in Illumina’s $8 billion acquisition of Grail
In an unusual step, the European Commission plans to intervene in the recent merger between…
STAT+: Pharmalittle: Key Senate panel proposes expanded pharma pricing penalties; Biden will urge Covid-19 summit to help poor nations get vaccines
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Is a Beyondspring drug helping lung cancer patients live longer? Study results trigger debate
Beyondspring’s stock price tripled in August after the New York drug maker said its experimental…
STAT+: Senate proposes expanding pharma penalties for hiking drug prices
WASHINGTON — A key Senate panel is expanding its plans to punish drug makers that…
STAT+: Former Mylan IT exec pleads guilty to insider trading on earnings, drug approvals, and merger
A former Mylan information technology executive pleaded guilty to an insider trading scheme in which…
STAT+: With new colon cancer study results, Mirati lays claim to best KRAS-blocking drug
A drug from Mirati Therapeutics designed to block the cancer protein called KRAS shrank tumors…
STAT+: ‘A solid black eye’: Drug pricing reform advocates scramble to reset after setback in Congress
WASHINGTON — For the cadre of progressive groups fighting to bring down drug prices in…
STAT+: U.K. government launches a new system to monitor clinical trial reporting
After a prolonged effort, the U.K. government is now tracking whether clinical trial sponsors are…
STAT+: Pharmalittle: FDA advisory panel to decide on Covid-19 boosters; Justice Dept. trustee appeals Purdue bankruptcy deal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: FDA scientists skeptical on boosters; moderate Democrats sink Pelosi’s drug pricing proposal
Good morning, all, I hope everyone is off to a good start. Ed is out…
STAT+: Drug makers failed to block House provision cracking down on orphan drug tax credits
WASHINGTON — Drug makers mounted a last-minute, and so far unsuccessful, campaign to kill a surprise…
Opinion: STAT+: Rewriting the playbook for digital therapeutics
The acceleration of investment in digital health and adoption of health-related apps triggered by the…
STAT+: A ‘wonky’ congressional report will be a pharma talking point in the drug pricing debate
As lawmakers in Washington grapple with legislation to alter the upward trajectory of prescription drug…
STAT+: Amgen combination treatment with KRAS-blocking drug shows improved response in colon cancer patients
A combination treatment that pairs Amgen’s KRAS-blocking drug Lumakras with another of its targeted cancer…
STAT+: Safety-net hospitals take big markups on cancer drugs for commercially insured patients, study finds
Hospitals participating in a federal drug discount program marked up cancer medicines four times for…
STAT+: After a court let them off the hook, generic Zantac makers plan to seek legal expenses from consumers
A few months ago, a federal court judge dismissed all claims against more than a…
STAT+: Stanford spins out a company to tap old patient data to answer new questions
A company is launching out of Stanford University on Wednesday to tackle one of the…
STAT+: Pharmalittle: Moderate Democrats threaten House drug-pricing bill; FDA reverses decision on reviewing ALS drug
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Digital health measures are gaining traction, but research on privacy and ethics is lagging
A catalyzing new review found virtually no research into ethics, security, and data rights of…
STAT+: Facing pressure from ALS patients and advocates, the FDA does about-face on review of potential treatment
The Food and Drug Administration has reversed an internal decision and will now review an…
STAT+: Key senator opposes Democrats’ target for drug-pricing savings
WASHINGTON — An influential Senate Democrat is pushing back against his party’s efforts to cut…
STAT+: Pharmalittle: Purdue execs get their bonuses; Woodcock, two senators push patent office over pharma abuse
Top of the morning to you, and a fine one it is. The sun is…
STAT+: FDA commissioner, two senators raise concerns about patent abuse by pharmaceutical companies
In a bid to address the high cost of medicines, Food and Drug Administration Commissioner…
STAT+: In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s
Cassava Sciences CEO Remi Barbier on Monday shifted his defense of the company’s embattled treatment…
STAT+: Pharmalittle: International experts argue against Covid-19 boosters; centrist House Dems to release separate drug-pricing proposal
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Cancer drug indications remain on labels even after trials fail to confirm their benefits
One-third of the uses for cancer drugs granted speedy approvals remained on product labeling even…
Opinion: STAT+: Combating the burnout bottleneck among clinical research workers
Health care professionals of all stripes were battling burnout and mental illness before the pandemic…
STAT+: After a decade at Facebook and Google, a tech exec tries his hand at drug development
After building Facebook’s search bar into a pivotal part of its platform, Tom Stocky is…
STAT+: Scientist Aubrey de Grey made inappropriate sexual comments to two female entrepreneurs, independent investigation finds
Aubrey de Grey, the anti-aging research pioneer who was removed last month as chief scientific…
STAT+: Biogen trials for Alzheimer’s drug excluded much of the targeted patient pool, study finds
A new analysis finds that the clinical trials conducted by Biogen (BIIB) for its controversial…
STAT+: Pharmalittle: Endo pays $50 million to settle opioid case; Senate mulls pegging drug prices to VA discounts
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
STAT+: The future of Apellis Pharma’s eye disease treatment is clouded by divergent study results
Apellis Pharmaceuticals has a good news-bad news problem involving its experimental treatment for geographic atrophy…
STAT+: For the first time, the FDA warns a trial investigator for failing to report study results
In a little noticed warning, the Food and Drug Administration threatened to fine the principal…
STAT+: Senate considers pegging Medicare drug prices to deeply discounted Veterans Affairs rates
WASHINGTON — Senate lawmakers are actively considering pegging the prices Medicare pays for drugs to…
STAT+: Pharmalittle: Biden drug-pricing plan backs Medicare negotiations; Moderna tests combined Covid-19 booster and flu shot
Good morning, everyone, and nice to see you again. We have finally returned from an…